ArticleAging clinical and experimental research2025
The association between chronic liver disease and osteoporosis in East Asian populations: a bidirectional Mendelian randomization study.
Article in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundChronic liver disease is a widespread health problem globally, particularly common in East Asia. Osteoporosis (OP), as a common metabolic bone disease, has also gained increasing attention in aging societies. In recent years, studies have suggested a possible association between chronic liver disease and OP, but their causal relationship has not been fully or systematically studied.
objectiveTo investigate the causal association between chronic liver disease and OP in East Asian populations using Mendelian randomization (MR) methods.
methodsThe datasets for chronic hepatitis B infection (CHB), chronic hepatitis C infection (CHC), and cirrhosis were sourced from the UK Biobank, while those for hepatocellular carcinoma (HCC) and OP were from the Japan Biobank. All participants included were from East Asian populations. We first treated chronic liver disease as the exposure and OP as the outcome for MR analysis, and then performed a reverse analysis treating OP as the exposure and chronic liver disease as the outcome. The inverse variance-weighted (IVW) method was used as the primary method to calculate odds ratios (ORs) and 95% confidence intervals (95% CIs). MR-Egger and the weighted median method were used as supplementary approaches to assess the causal association between chronic liver disease and OP. Heterogeneity and pleiotropy tests were also performed to ensure the reliability of the results.
resultsThe IVW method results indicated that CHB (ebi-a-GCST90018584) will increase the incidence of OP (bbj-a-137) (OR = 1.063, 95% CI: 1.015-1.112, p = 0.009), with no evidence of heterogeneity or pleiotropy. However, no causal association was found between CHC, cirrhosis, or HCC on OP. Reverse MR analyses did not reveal any significant causal effect of OP on chronic liver disease.
conclusionIn East Asian populations, CHB will increase the incidence of OP. Therefore, CHB patients not only require long-term antiviral treatment to protect the liver but should also monitor their bone health over time to reduce the risk of OP, ultimately improving quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.